Acetyl-L-carnitine

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada. The CPI-818 data was presented by John Reneau, MD, PhD, from The Ohio State University Comprehensive Cancer Center. Dr. Reneau is a hematologist who specializes in treating patients with lymphoma and an investigator for the Phase 1/1b clinical trial of CPI-818 for TCL. “T cell lymphoma is a challenging disease to treat and there is significant need for new approaches given the limited efficacy of current therapeutic options,” said Dr. Reneau. “CPI-818 has a novel mechanism of action that includes the stimulation of normal T cells to infiltrate and destroy tumors. Our recent work indicates that the peripheral blood absolute lymphocyte count is a biomarker that may predict patients most likely to benefit from CPI-818. This positions our trial to build on the results CPI-818 has already demonstrated - monotherapy activity in advanced, relapsed patients, with potential for higher response rates driven by this new biomarker.” CPI-818 Phase 1/1b T Cell Lymphoma Data CPI-818 is currently being studied in a Phase 1/1b clinical trial as a single agent therapy in patients with relapsed TCL. As of February 23, 2023, 20 patients were enrolled in the 200 mg cohort (optimal dose), including 13 evaluable for tumor response. There have been 1 complete response (CR) of 24 months duration, 1 equivocal CR awaiting confirmatory PET scan of 13+ months duration (a previous partial response (PR)), 1 nodal CR of 21 months duration and 1 PR of 7 months duration. Ten patients continue on therapy, including seven who have not yet been evaluated for tumor response. Corvus has identified minimum absolute lymphocyte count (ALC) above 900 per cubic milliliter of blood as a biomarker associated with response to CPI-818. Interim data from the 200 mg cohort in the Phase 1/1b clinical trial indicate that this minimum ALC level is required for tumor response and disease control. As of February 23, 2023, four of eight patients with ALC above 900 had objective responses (those four patients are described above), all eight had disease control (stable disease, PR, CR) and the median progression free survival (PFS) was 28.1 months. No objective responses were seen in five patients (0 of 5) with ALC below 900 and the PFS was 2.1 months. New interim data, as of February 23, 2023, presented by Dr. Reneau evaluated the effect of ALC on PFS of patients based on their last prior chemotherapy treatment before receiving CPI-818. There was no significant difference in the PFS achieved in patients with ALC less than 900 per cubic milliliter (PFS = 3.2 months) compared to patients with ALC greater than or equal to 900 per cubic milliliter (PFS = 3.4 months), which suggests the ALC biomarker is not predictive for standard therapies. This result is consistent with CPI-818’s proposed mechanism of action, which involves the enhancement of normal lymphocyte function, and indicates that the improved results seen with CPI-818 in patients with ALC above 900 is not due to more favorable patient characteristics. The swimmer and waterfall tumor plots for these patients, along with the data summarizing the ALC biomarker data, are included in Dr. Reneau’s presentation slides, which are available on the Publications and Presentations page of the Corvus website. “The data from our Phase 1/1b trial of CPI-818 for T cell lymphoma continues to be strong, with durable and deep tumor responses observed to date,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We are encouraged that enrollment has accelerated and that we have implemented a biomarker that we believe will enable us to enroll patients most likely to benefit from CPI-818, which is of particular importance as we plan for a registration Phase 3 randomized clinical trial. I want to thank Dr. Reneau and all our investigators for their participation in the trial and for the work they do in support of patients.” About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor that is in an open-label Phase 1b/2 clinical trial. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit . About CPI-818 CPI-818 is an investigational small molecule drug given orally that has selectively inhibited ITK (interleukin-2-inducible T cell kinase) in preclinical studies. It was designed to block malignant T cell growth and to modulate immune responses. ITK, an enzyme, is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function. Recent clinical data in T cell lymphomas suggests that CPI-818 has the potential to control differentiation of T helper cells and enhance immune responses to tumors. Interference with ITK signaling also can modulate immune responses to various antigens. Optimal doses of CPI-818 have been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of Th2 related cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The immunologic effects of CPI-818 lead to what is known as Th1 skewing and is made possible by the high selectivity of CPI-818 for ITK. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with T cell lymphomas, solid tumors, and in patients with autoimmune and allergic diseases. The Company is conducting a Phase 1/1b trial in patients with refractory T cell lymphomas that was designed to select the optimal dose of CPI-818 and evaluate its safety, PK, target occupancy, immunologic effects, biomarkers and efficacy. Interim data from the Phase 1/1b clinical trial of CPI-818 for T cell lymphoma demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, and identified a dose that maximally affects T helper cell differentiation. Forward-Looking Statements This press release contains forward-looking statements, including statements related to the potential safety and efficacy of CPI-818, ciforadenant and mupadolimab; the Company’s ability to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including the Company Phase 1/1b clinical trial of CPI-818 and the Company’s planned Phase 3 registration clinical trial with CPI-818 for T cell lymphoma; the design of clinical trials, including the target number of patients to be enrolled and whether identifying certain biomarkers will help accelerate enrollment; and the timing of the availability and announcement of clinical data and certain other product development milestones. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of CPI-818, ciforadenant and mupadolimab; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 llea@corvuspharma.com MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 sseapy@realchemistry.com

Delaware, Jan. 09, 2021 (GLOBE NEWSWIRE) -- Welcome to read our honest & real Promind Complex supplement customer reviews you should learn list of ingredients, side effects, Promind Complex scam or legit & complaints. Memory loss takes a toll on one’s life- physically, emotionally, and socially. Generally, this problem of brain function is caused by a host of factors which include genetics, age, and even, diet. However, according to the Promind Complex official site, memory loss can be caused by bacterial infection too - the same plaque-forming bacteria that swarm your teeth and gums. Additionally, memory loss comes with a host of other effects like headaches and low energy. The good news is that one can use the Promind Complex ingredients to address memory loss according to the official website. The Promind Complex supplement improves memory function whilst fortifying the body and protecting it against bacterial infection. Plus, to use the supplement, one doesn't have to adopt strict diets or change their lifestyle. Product TitlePromind ComplexTypeSupplementPen NameCarl HendersonCategoryMemory BoosterPrice$69(Check For Discounted Price)Official WebsiteClick Here What Is Promind Complex? The Promind Complex ingredients is a premium formula designed to clear the brain of plaque forming bacteria and protect it against dental nerve bacterial that form plaque and cause memory loss. According to the official site, the Promind Complex supplement is formulated using natural ingredients for a toxic free performance. How Does Promind Complex work? The Promind Complex supplement is formulated to work in two phases. The first phase integrates three key steps. Step 1 The first step helps to eradicate bacteria. It does this by using huperzine. In this process, bacteria are removed from the brain's surface to prevent future infections. Step 2 The second step is to repair wounded brain cells that were damaged by the plaque build up. In this process, another natural ingredient, vinpocetine is used. Step 3 The third step is to protect the brain and gums against bacteria; forming a bulletproof coat around them. during the third step, the herb ginkgo Biloba is used. The second phase of how the supplement works consists of four useful ingredients that deliver mind-clearing properties for increased mental clarity and memory retention. The phase integrates four key steps which include; Step 1 The first step of the second phase is to fire up the brain cell communication. In the first step to the second phase, the ingredient phosphatidylserine plays an important role. Step 2 The second step is to scrape off the plaque already built up in the brain. In this process, a naturalnutrient, St. John's wort is used. Step 3 The third step is to eliminate anxiety and depression. This step uses the Bacopa monnieri. Step 4 The final step is to eliminate brain fog and insomnia. At the same time, the supplement leaves one full of energy. The supplement used acetyl-L-carnitine. Check 2021 Latest Updated Discounted Promind Complex Price Details Promind Complex Ingredients As stated above, the Promind Complex supplement uses its natural ingredients in two key phases. The ingredients include; Huperzine This Huperzine natural herb boasts antibacterial properties which allow it to tackle bacteria on the brain's surface. In addition to killing the harmful bacteria, it provides a protective coating on the rain to prevent future bacterial infections. Vinpocetine Vinpocetine is known to heal the brain cell by opening up the brain blood vessels. As the vessels open, enough oxygen is delivered to the nerve cells thus, bring them back to life. As the cells begin to work and ample blood flows through the brain, the healing cells flush out cerebral toxins whilst acquiring back one's memory retention capacity. Ginkgo Biloba This natural root provides a protective coat around the brain and gums to prevent infection-causing microbial build up. Phosphatidylserine This ingredient ends in promoting healthier brain cell membranes. The ingredient works like a wall that protects the membrane against toxic elements. Thanks to this protective performance, your cells continue to be enriched to promote memory retention and superior brain functioning. St. John’s Wort St. John's Wort is added to clean up the hardened plaque in the brain. With proper cleaning, the brain will begin to allow for optimal blood flow and brain cell communication for better mental functions. Bacopa Monnieri Bacopa Monnieri is known to reduce stress and depression by lowering the stress hormone levels in the bloodstream. This leaves one with a clearer and healthier mind. Acetyl-L-Carnitine This L-Carnitine amino acid is responsible for restoring memory function by smoothening the neurotransmitters and increasing their responsiveness. At the same time, this amino acid helps to reduce stress and uplift one’s mood. Learn more about the science behind Promind Complex ingredients Promind Complex Dosage As a daily recommended dosage of Promind Complex capsules, according to the official website, one should take 2 capsules of the supplement with a large meal daily. This can be breakfast or lunch. Generally, one should take the capsules for at least 60 days before they begin to notice any changes. However, even with the changes, it is advised that one takes the supplements for at least 6 months straight for optimal results. According to the makers of the supplement, this duration gives the supplement enough time to work on your brain and provide it with an adequate protective coating. To ensure the supplement works, it is also advised to take the capsules daily and to refrain from skipping days. A single Promind Complex supplement bottle comes with 30 capsules; meaning it will last for a month. Promind Complex Pricing The Promind Complex ingredients formula is available for purchase at its official site in a choice of three package offers. According to the official website, the supplement is only available for purchase on the official site to prevent scammers and duplicators. Therefore, when one searches for it in other marketplaces like Amazon or Walmart, they will not be successful. For the 30-day package offer, one will receive a single 30-capsule bottle for only $69 instead of $99 with free shipping; allowing them to save $30 in the process. Alternatively, they can opt for the 60-day package offer which comes with three capsule bottles; each costing $59 with free shipping. This allows one to save up to $177. However, for the best package value, one can opt for the 90-day package. This package comes with up to six 30-capsule bottles; each costing $49 with free shipping. This allows one to save a whopping $294. Upon payment, delivery is done to one’s doorstep within 5 to 7 business days. However, one will not only receive the supplements. Each supplement purchase comes with a 60-day money-back guarantee. This means that within 2 months of purchasing the supplements if one doesn't notice any results, they can always request a full refund with no questions asked. Must Check current Promind Complex pricing Promind Complex Reviews - Final Verdict With the Promind Complex ingredients, one will enjoy improved mental functions, alertness, and restored memory retention. What sets this supplement apart, according to its official website is that it energizes your body in the process whilst also protecting the brain and gum from future bacterial infections. At the end of the day, one will enjoy a revitalized brain and body. However, one must keep in mind that the Promind Complex is simply a dietary supplement. Therefore, one shouldn't take it as a replacement for their subscription medication. Instead, before one even begins to use it like a dietary supplement, they should consult their physician to find out if it is safe for them or not. For individuals such as pregnant women or women who are breastfeeding, it is advised against using the Promind Complex supplement. Act now and take full advantage of the Promind Complex supplement today by ordering directly from the official website at promindcomplex.com Product Support: contact@promindcomplex.com About: DietCare Reviews DietCare Reviews shares e-commerce and sales news, product reviews and latest news on various products. This review for informational purposes only. The information does not constitute advice or an offer to buy. Any purchase done from this story is done on your own risk. Consult an expert advisor / health professional before any such purchase. Any purchase done from this link is subject to final terms and conditions of the website that is selling the product. The content on this release does not take any responsibility directly or indirectly. Contact: Dietcarereviews ( contact@dietcarereviews.com ) The FDA will never approve a dietary supplement. According to the Food and Drug Administration, dietary supplements are a category of their own, and they are not subject to FDA regulation or approval. If a company is claiming that the FDA approves their diet supplement, run. This is a clear misrepresentation. -This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. --- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This news has been published for the above source. DietCare Reviews [ID=16277] KISS PR PRODUCT REVIEWER COMPENSATION DISCLOSURE Pursuant to the Federal Trade Commission's guidance of the public in conducting its affairs in conformity with legal requirements comprised in 16 C.F.R. § 255 et seq. on the use of endorsements and testimonials in advertising, this Product Reviewer Compensation Disclosure is provided by KissPR.com LLC and its affiliated entities (hereinafter referred to collectively as “KISS PR”). This disclosure applies to content displayed on all mobile, desktop, and other online versions of KISS PR’s websites and to those of KISS PR’s distribution partners (hereinafter referred to collectively as “the Websites”) and is provided for the purpose of disclosing the nature of the connection between KISS PR and product reviewers, advertisers, sponsors, endorsers, and other third-parties whose advertisements, sponsorships, endorsements, testimonials, opinions, or other product-related or service-related statements or reviews may appear on the Websites (hereinafter referred to as an "Product Reviewer"). This Product Reviewer Compensation Disclosure is intended to disclose to you that in consideration of payment of monetary and other compensation from a Product Reviewer, as described below, KISS PR sells various advertising, sponsorships, and marketing campaigns that are featured on one or more of the Websites. There is a financial connection related to some of the products or services mentioned, reviewed, or recommended on the Websites between KISS PR and the Product Reviewer that owns, markets, or sells such product or service. If you decide to purchase a product or service featured on one or more of the Websites, KISS PR will not receive compensation related to that purchase from a Product Reviewer but may receive a one-time fee from the Product Reviewer for posting or distributing the product review on or via the Websites. Further, KISS PR may post or otherwise promote on the Websites content, including editorial content, which may feature third-party products and services (a "Reviewed Product"). This content may contain weblinks to third-party owned or operated web sites where you can purchase Reviewed Product (“Product Link”). If you click on a Product Link and then purchase a Reviewed Product on the linked web site, KISS PR will not receive compensation from the third-party offering the Reviewed Product (the “Vendor”). Weblinks on the Websites featuring a Reviewed Product may be added to posts or articles that are not identified on the Websites as comprising or containing paid or sponsored content. In such case, a disclosure statement about the Reviewed Product and the compensation that KISS PR might receive in connection with its purchase by you will be included in such posts or articles. Further, third-party advertisements may be posted on the Websites. Each time you click on such an advertisement, KISS PR may receive compensation from the third-party advertiser, even if you do not purchase any product or service from that third-party. KISS PR will, subject to the disclaimer of liability set forth below, endeavor to ensure that product or service endorsements appearing in the Websites or in posts or articles distributed via the Websites reflect the honest opinions, findings, beliefs, or experiences of the Product Reviewer as they relate to such product or service. If you have any complaint, concern, or question relating to the content of any such post or article, including alleged infringement of any intellectual property rights, you should address your complaint, concern, or question directly to the Product Reviewer or the Vendor. NO REPRESENTATIONS OR WARRANTIES; NON-RELIANCE. EXCEPT FOR ANY EXPRESS REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS DISCLOSURE STATEMENT, NEITHER KISS PR NOR ANY OTHER PERSON ON KISS PR’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, EITHER ORAL OR WRITTEN, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE, TRADE, OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND YOU ACKNOWLEDGE THAT YOU HAVE NOT RELIED UPON ANY REPRESENTATION OR WARRANTY MADE BY KISS PR OR ANY OTHER PERSON ON KISS PR’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN THIS DISCLOSURE STATEMENT. DISCLAIMER OF LIABILITY. IN NO EVENT SHALL KISS PR BE LIABLE OR RESPONSIBLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR LOST OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND REGARDLESS OF THE CAUSE OF ACTION UPON WHICH ANY SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY OF THE CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OF OR THE ACCURACY OF ANY STATEMENT MADE IN OR OMITTED FROM ANY ADVERTISEMENT, SPONSORSHIP, ENDORSEMENT, TESTIMONIAL, OPINION, OR OTHER PRODUCT-RELATED OR SERVICE-RELATED STATEMENT OR REVIEW APPEARING IN THE WEBSITES OR IN ANY POST OR ARTICLE DISTRIBUTED VIA THE WEBSITES. © 2021 KissPR.com LLC Media Contact Website: [KISS PR Brand Story PressWire] - Email: Media@kisspr.com Attachment Promind Complex Reviews - Ingredients & Side Effects